Medicine Overview of Uronase 500000IU/10ml Injection
Uronase is a medicine used to break down harmful blood clots that have formed in the blood vessels. It is used to treat patients who have suffered a recent heart attack. It is also used in treating conditions such as pulmonary embolism and stroke.
Uronase is administered under the supervision of a doctor. Your doctor will decide the dose and duration of the medicine for you. The doctor may closely monitor your condition till you became stable.
Use of this medicine may cause nausea, injection site bleeding, allergic reaction, and decrease in blood pressure. It may increase your risk of bleeding also. Your doctor will explain the benefits and risks associated with this medicine before it is administered. You should continue all your other medicines that are advised by the doctor for your long-term treatment even after this injection.
This medicine is used with caution for some people. Thus, you must inform the doctor if you are suffering from any bleeding disorder, kidney or liver disease. Also, let your doctor know if you are pregnant or breastfeeding and about all the other medications that you are taking regularly.
- Heart attack
- Pulmonary embolism
- Allergic reaction
- Nausea
- Vomiting
- Injection site bleeding
-
It increases your risk of bleeding. Be careful while shaving, cutting fingernails or toenails, using sharp objects or engaging in contact sports (e.g. football, wrestling).
-
Do not discontinue use without consulting your doctor as this may increase your chances of having another heart attack or stroke.
Intravenous
Deep vein thrombosis
Adult: Initially, 4400 units/kg dissolved in 15 ml of sodium chloride 0.9%, infused IV over 10 minutes followed by 4400 units/kg/hr for 12-24 hr.
Parenteral
Acute myocardial infarction
Adult: 6000 units/min infused into the coronary artery for 2 hr preceded by IV heparin. Alternatively, 2-3 million units IV is given over 45-90 min.
Intravenous
Peripheral arterial thromboembolism
Adult: As solution containing 2000 units/ml: Infuse into the clot via a catheter at a rate of 4000 units/minute for 2 hr. Monitor response using angiography. If clot is not removed, advance the catheter into the occluded vessel and continue infusion at the same rate for another 2 hr. May repeat procedure, if needed, up to 4 times. Once blood flow is re-established, partially withdraw the catheter and continue infusing at 1000 units/minute until the remaining clot has lysed.
Pulmonary embolism
Adult: Initially, 4400 units/kg dissolved in 15 ml sodium chloride 0.9%, infused over 10 min followed by 4400 units/kg/hr for 12 hr. Alternatively, 15000 units/kg as bolus Inj into the pulmonary artery; may repeat inj, adjust dose according to plasma fibrinogen concentrations up to 3 times in 24 hr.
Injection
Clearance of occluded catheters and shunts
Adult: 5000 – 25000 units in 2 ml sodium chloride 0.9% instilled into affected IV catheter or shunt and clamped for up to 4 hr. Aspirate the lysate and repeat the procedure if needed. Alternatively, infuse a solution containing 5000 units of urokinase in 200 mL of sodium chloride 0.9% into the device over 30 minutes.
Irrigation
Break down of clots in hyphaema
Adult: To prepare the solution: Dissolve 5000 units in 2 ml of sterile distilled water. Irrigate the anterior chamber slowly with 0.3 ml of the solution; leave solution in situ for 3 minutes and then wash out with saline. Repeat procedure 5 times. If residual clot is still present at the end of the treatment, leave 0.3 ml of the solution in the anterior chamber for 24-48 hr.
Bleeding, pyrexia, haematuria, thromboembolic episodes, hypersensitivity reactions.
Potentially Fatal: Severe bleeding, anaphylaxis.
Reduced thrombolytic effect when given again some time later due to development of high levels of antibodies.
Potentially Fatal: Platelet inhibitors eg, aspirin and indometacin can potentiate the action of urokinase and cause haemorrhage. Heparin and oral anticoagulants may increase risk of bleeding.
Reviews
Clear filtersThere are no reviews yet.